Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2013

01-10-2013 | Research Article

Overexpression of CRKL correlates with malignant cell proliferation in breast cancer

Authors: Tingting Zhao, Zhifeng Miao, Zhenning Wang, Yingying Xu, Jianhua Wu, Xingyu Liu, Yi You, Jiguang Li

Published in: Tumor Biology | Issue 5/2013

Login to get access

Abstract

Crk-like (CRKL) is an adapter protein that has crucial roles in multiple biological processes, including cell proliferation, adhesion, and migration. However, the expression pattern of CRKL protein and its clinical significance in human breast cancers have not been well characterized. In this study, expression of CRKL was evaluated in 108 human invasive ductal carcinoma (IDC) tissues by immunohistochemistry. CRKL protein was upregulated in the cancer tissues compared with adjacent normal mammary glands. Overexpression of CRKL was found in 40 of 108 (37.03 %) breast cancer samples and correlated with advanced p-tumor–node–metastasis stage (p = 0.002), nodal metastasis (p = 0.0323), and tumor size (p = 0.0075). In addition, overexpression of CRKL in the MDA-MB-435 cell line promoted cell proliferation, and small interfering RNA knockdown of CRKL in the MDA-MB-453 cell line inhibited proliferation. Further analysis of cell cycle-related molecules showed that CRKL induced cyclin D1 and phosphorylated extracellular signal-regulated kinase expression. In conclusion, this study demonstrated that overexpression of CRKL correlated with progression and malignant proliferation of human breast cancers.
Literature
1.
2.
Kabbage M, Trimeche M, Ben Nasr H, Hammann P, Kuhn L, Hamrita B, et al. Expression of the molecular chaperone alphaB-crystallin in infiltrating ductal breast carcinomas and the significance thereof: an immunohistochemical and proteomics-based strategy. Tumour Biol. 2012;33(6):2279–88.CrossRefPubMed
3.
Elfagieh M, Abdalla F, Gliwan A, Boder J, Nichols W, Buhmeida A. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer. Tumour Biol. 2012;33(6):2371–7.CrossRefPubMed
4.
ten Hoeve J, Morris C, Heisterkamp N, Groffen J. Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene. 1993;8(9):2469–74.PubMed
5.
Feller SM. Crk family adaptors-signalling complex formation and biological roles. Oncogene. 2001;20(44):6348–71.CrossRefPubMed
6.
ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia + leukemia. Blood. 1994;84(6):1731–6.PubMed
7.
ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N, et al. Cellular interactions of CRKL, and SH2-SH3 adaptor protein. Cancer Res. 1994;54(10):2563–7.PubMed
8.
Senechal K, Halpern J, Sawyers CL. The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem. 1996;271(38):23255–61.CrossRefPubMed
9.
Hemmeryckx B, van Wijk A, Reichert A, Kaartinen V, de Jong R, Pattengale PK, et al. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice. Cancer Res. 2001;61(4):1398–405.PubMed
10.
Singer CF, Hudelist G, Lamm W, Mueller R, Handl C, Kubista E, et al. Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep. 2006;15(2):353–9.PubMed
11.
Kim YH, Kwei KA, Girard L, Salari K, Kao J, Pacyna-Gengelbach M, et al. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene. 2011;29(10):1421–30.CrossRef
12.
Ladanyi M. CRKL as a lung cancer oncogene and mediator of acquired resistance to EGFR inhibitors: is it all that it is cracked up to be? Cancer Discov. 1(7):560-1.
13.
Wang Y, Dong QZ, Fu L, Stoecker M, Wang E, Wang EH. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer. Mol Carcinog. 2012. doi:10.​1002/​mc.​21935.
14.
Feller SM, Knudsen B, Wong TW, Hanafusa H. Detection of SH3-binding proteins in total cell lysates with glutathione S-transferase-SH3 fusion proteins: SH3 blot assay. Methods Enzymol. 1995;255:369–78.CrossRefPubMed
15.
Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, et al. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem. 1995;270(49):29145–50.CrossRefPubMed
16.
Mintz PJ, Cardo-Vila M, Ozawa MG, Hajitou A, Rangel R, Guzman-Rojas L, et al. An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment. Proc Natl Acad Sci U S A. 2009;106(7):2182–7.PubMedCentralCrossRefPubMed
17.
18.
Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4(12):937–47.CrossRefPubMed
19.
Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009;69(2):565–72.PubMedCentralCrossRefPubMed
20.
Nosaka Y, Arai A, Miyasaka N, Miura O. CrkL mediates Ras-dependent activation of the Raf/ERK pathway through the guanine nucleotide exchange factor C3G in hematopoietic cells stimulated with erythropoietin or interleukin-3. J Biol Chem. 1999;274(42):30154–62.CrossRefPubMed
21.
Shi Y, Chen L, Li J, Lv YL, Sun Q, Wang LX, et al. Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol. 2011;32(2):381–90.CrossRefPubMed
22.
Dong QZ, Wang Y, Tang ZP, Fu L, Li QC, Wang ED, et al. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Am J Pathol. 2013;182(3):954–64.CrossRefPubMed
Metadata
Title
Overexpression of CRKL correlates with malignant cell proliferation in breast cancer
Authors
Tingting Zhao
Zhifeng Miao
Zhenning Wang
Yingying Xu
Jianhua Wu
Xingyu Liu
Yi You
Jiguang Li
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0851-7

Other articles of this Issue 5/2013

Tumor Biology 5/2013 Go to the issue

Research Article

Evaluation of a CLEIA automated assay system for the detection of a panel of tumor markers

Research Article

GSTM1 and GSTT1 polymorphism and susceptibility to esophageal cancer in high- and low-risk regions of India

Research Article

Myeloperoxidase G463A polymorphism and lung cancer risk in Asians: a pooled analysis

Research Article

Numblike regulates proliferation, apoptosis, and invasion of lung cancer cell

Research Article

Inhibition of mTOR and HIF pathways diminishes chondro-osteogenesis and cell proliferation in chondroblastoma

Research Article

Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits